Daige CL - Search Results

1

Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Trang P, et al. Among authors: daige cl. Mol Ther. 2011 Jun;19(6):1116-22. doi: 10.1038/mt.2011.48. Epub 2011 Mar 22. Mol Ther. 2011. PMID: 21427705 Free PMC article.

2

Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer.

Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J, Brown D. Daige CL, et al. Mol Cancer Ther. 2014 Oct;13(10):2352-60. doi: 10.1158/1535-7163.MCT-14-0209. Epub 2014 Jul 22. Mol Cancer Ther. 2014. PMID: 25053820

3

Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.

Badeaux MD, Rolig AS, Agnello G, Enzler D, Kasiewicz MJ, Priddy L, Wiggins JF, Muir A, Sullivan MR, Van Cleef J, Daige C, Vander Heiden MG, Rajamanickam V, Wooldridge JE, Redmond WL, Rowlinson SW. Badeaux MD, et al. Cancer Immunol Res. 2021 Apr;9(4):415-429. doi: 10.1158/2326-6066.CIR-20-0317. Epub 2021 Jan 26. Cancer Immunol Res. 2021. PMID: 33500272

4

Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression.

Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED, Petrowski M, Jepsen K, Baek SH, Heyman RA, Rosenfeld MG, Schulman IG, Glass CK. Wagner BL, et al. Among authors: daige cl. Mol Cell Biol. 2003 Aug;23(16):5780-9. doi: 10.1128/MCB.23.16.5780-5789.2003. Mol Cell Biol. 2003. PMID: 12897148 Free PMC article.

5

Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists.

Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG. Levin N, et al. Among authors: daige cl. Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42. doi: 10.1161/01.ATV.0000150044.84012.68. Epub 2004 Nov 11. Arterioscler Thromb Vasc Biol. 2005. PMID: 15539622

6

Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC, Schulman IG. Bischoff ED, et al. Among authors: daige cl. J Lipid Res. 2010 May;51(5):900-6. doi: 10.1194/jlr.M900096. J Lipid Res. 2010. PMID: 20388921 Free PMC article.

7

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Flatt B, et al. J Med Chem. 2009 Feb 26;52(4):904-7. doi: 10.1021/jm8014124. J Med Chem. 2009. PMID: 19159286

8

Identification of macrophage liver X receptors as inhibitors of atherosclerosis.

Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG. Tangirala RK, et al. Among authors: daige cl. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11896-901. doi: 10.1073/pnas.182199799. Epub 2002 Aug 22. Proc Natl Acad Sci U S A. 2002. PMID: 12193651 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters